Description
FOXO4-DRI is a synthetic D-retro-inverso peptide (DRI) that disrupts the protein-protein interaction between FOXO4 and p53 in senescent cells. Structurally it is a modified peptide with D-amino acids in reversed sequence, which makes the compound resistant to proteolytic degradation and extends its half-life. FOXO4-DRI is one of the most prominent senolytic compounds in anti-aging research.
The research mechanism lies in the targeted elimination of senescent cells. Senescent cells are no longer proliferating cells that accumulate in aging tissue and cause chronic inflammation and tissue dysfunction through their senescence-associated secretory phenotype (SASP). In preclinical studies it was shown that senescent cells use FOXO4 to sequester p53 and thus suppress the apoptotic response.
FOXO4-DRI breaks this interaction. p53 is released and can exert its apoptotic function. Senescent cells are selectively eliminated. In the landmark 2017 Cell paper from the Peter de Keizer lab, this mechanism was characterized and associated with dramatic effects in mouse aging models: improved kidney function, increased physical activity, restored fur density.
In research setups, FOXO4-DRI is one of the most intensively discussed senolytic tools. The data focuses on preclinical animal models. Clinical studies are in early phases.
FOXO4-DRI is available in 5mg vials as 10-vial packs.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
FOXO4-DRI is a senolytic compound that actively drives senescent cells into apoptosis. This interventional mechanism sets the profile apart from that of milder anti-aging peptides.
Documented in the preclinical literature:
- Pro-apoptotic mechanism: through the release of p53, the apoptotic response is activated. In animal models this effect is focused on senescent cells, but the selectivity in humans is not validated.
- No robust human data: clinical studies are in early phases. Statements on tolerability and dosing in humans cannot be derived from the literature.
- Injection site: as a parenterally applied peptide, irritation at the injection site is to be expected.
- Circulation: animal models describe transient systemic reactions following application.
- Mechanistically interventional: a compound that actively triggers cell death naturally has a different risk profile than purely regenerative peptides, even though the preclinical data is limited to senescent cells.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Targeted apoptosis of senescent cells via FOXO4-p53 - Cell 2017: Original characterization of the compound.
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice - Aging 2020: FOXO4-DRI disrupted the FOXO4-p53 interaction in senescent Leydig cells and selectively induced apoptosis there. In naturally aged mice the testicular microenvironment improved and the age-related decline in testosterone secretion was alleviated.
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes - Frontiers in Bioengineering and Biotechnology 2021: In extensively expanded human chondrocytes, FOXO4-DRI removed more than half of the cells and lowered the senescence level while leaving minimally expanded cells unaffected, but it did not enhance chondrogenic potential.
- Senolytics improve physical function and increase lifespan in old age - Nature Medicine 2018: Context on the senolytic class, not on FOXO4-DRI itself: transplanting senescent cells caused physical dysfunction in young mice, while the combination of dasatinib plus quercetin alleviated it and increased post-treatment survival in old mice by 36%.
